MedTrace Logo

The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-associated Pneumonia (VAP)

NCT00498121 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2009-12-18

No results posted yet for this study

Summary

Our aim in this study is to investigate the potential role of serum ProCT as an early diagnostic marker and later prognostic indicator for VAP.

Conditions

  • Ventilator Associated Pneumonia

Interventions

DEVICE

PROCALCITONIN LEVEL

measuring PROCALCITONIN LEVEL

Sponsors & Collaborators

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Salman A Qureshi, MD,FRCPSC · McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Completion
2009-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00498121 on ClinicalTrials.gov